Welcome to our dedicated page for Cheelcare news (Ticker: CHCRF), a resource for investors and traders seeking the latest updates and insights on Cheelcare stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cheelcare's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cheelcare's position in the market.
Cheelcare (TSXV: CHER) entered term sheets for a non-brokered unsecured note financing of up to $1,000,000, expected to include $750,000 from Pathfinder Asset Management Ltd. and $250,000 from NameSilo Technologies.
The Notes carry an 18-month term at 12% annual interest, with interest payable semi-annually and principal due at maturity. The company may redeem after one year without penalty. Cheelcare will issue an aggregate 132,450 Bonus Shares (20% of principal over $1.51/share) subject to a four-month hold. Closing remains subject to customary corporate and Exchange approvals.
